Receiving the award at the Bangalore Technology Summit, on Friday, November 30,2018, Dr. Sunit Maity , Director-Product Development at Zumutor said “We have raised additional funds this year from our lead investor for ongoing development of our lead immuno oncotherapy molecule to enable IND filing in 2019”.
- By Sonali Karhana - Despite recent diagnostic and therapeutic advances, prostate adenocarcinoma is the second most common cancer in the Western male population. One in 7 men over the age of 50 years are diagnosed with prostate cancer at some point in their lives. “The first step toward ending this disease, which takes the [...]
- By Ramon Valencia, Vice president-Corporate Development & Strategy - The focus of immunotherapy over the last decade has been activating or re-activating T cells. A lesser known, but no less important to healthy immune function, is an immune cell called a natural killer (NK) cell. . NK cells “natural killer” are named so [...]
